Article

Safety of the Fourth COVID-19 BNT162b2 mRNA (Second Booster) Vaccine

2022-06-24

Abstract excerpt

Background: COVID-19 remains a global concern due to vaccine protection waning and the emergence of immune-evasive variants. While the effectiveness of a second booster vaccine dose (i.e., fourth inoculation) is well proven, its safety has yet to be fully understood. This lack of sufficient vaccine safety information is one of the key contributors to vaccine hesitancy. <br><br>Methods: To evaluate the safety of th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 070f0ee4-0b74-521e-9099-c1d39c2680f9
DOI: 10.2139/ssrn.4145588

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety of the Fourth COVID-19 BNT162b2 mRNA (Second Booster) VaccineDOI 10.2139/ssrn.4145588Read

Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity Read

Bivalent BNT162b2mRNA original/Omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared to the monovalent COVID-19 boosterSemantic proximity Read

Second Booster Vaccine Dose for Older Adults and COVID-19 Mortality During the Omicron SurgeSemantic proximity Read

Incidence and Nature of Adverse Events Following COVID-19 Second Boosters: Insights from Taiwan's Universal Vaccination StrategySemantic proximity Read

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidenceSemantic proximity Read

Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccinationSemantic proximity Read

The Effectiveness of the First Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World EvidenceSemantic proximity Read

BNT162b2 vaccine booster dose protection: A nationwide study from IsraelSemantic proximity Read

A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study)Semantic proximity Read

Reanalysis of the Pfizer mRNA BNT162b2 SARS-CoV-2 vaccine data fails to find any increased efficacy following the boost: Implications for vaccination policy and our understanding of the mode of actionSemantic proximity Read

Sex differences in symptoms following the administration of BNT162b2 mRNA Covid-19 Vaccine in Children below 5 Years of age in Germany (CoVacU5): a retrospective cohort studySemantic proximity Read

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 VaccineSemantic proximity Read